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Background: Recent studies have found that rifampicin has neuroprotective properties
in neurodegenerative diseases. However, the exact mechanisms of action remain unclear.
The nuclear factor erythroid 2-related factor 2 (Nrf2) has been considered a potential
target for neuroprotection. In this study, we examined whether rifampicin exhibits
beneficial effects mediated by the Nrf2 pathway after global cerebral ischemia (GCI).
Methods: Rats were randomly assigned to four groups that included a sham
group and three treatment groups with global ischemia-reperfusion [control, rifampicin,
and rifampicin plus brusatol (an inhibitor of Nrf2)]. Rats were subjected to transient
GCI induced by bilateral common carotid artery occlusion for 20 min with systemic
hypotension by blood withdrawal. The Morris water maze test was performed for
neurobehavioral testing, whereas the pathological changes were investigated using HE
and TUNEL staining. The protein expression of Nrf2, hemeoxygenase-1 (HO-1) and
cyclooxygenase-2 (COX-2) in the hippocampus were analyzed by Western blotting. The
immunofluorescence staining was used to determine the distribution of Nrf2.
Results: Rifampicin treatment significantly improved spatial learning ability compared
with the control group, which was consistent with the pathological changes. In addition,
rifampicin significantly elevated the nuclear expression of Nrf2, Nrf2 downstream
anti-oxidant protein, HO-1 compared with the control group, and it simultaneously
downregulated the expression of COX-2 in the hippocampus on day 3 after
ischemia-reperfusion. Interestingly, the forenamed effects of rifampicin were abolished
by pretreatment with brusatol, a specific inhibitor of Nrf2 activation.
Conclusions: Rifampicin exerts neuroprotective effects against global cerebral
ischemia, which may be attributed to activation of the Nrf2 pathway.
Keywords: rifampicin, global cerebral ischemia, delayed neuronal death, nuclear factor erythroid 2-related factor
2, heme oxygenase-1, cyclooxygenase-2
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INTRODUCTION
Global cerebral ischemia (GCI) is a clinical outcome that
can occur as a consequence of conditions including cardiac
arrest, severe dysrhythmias, reversible severe hypotension
(Liang et al., 2008). Transient GCI is a cerebrovascular
condition that diminishes the cerebral blood flow by up
to 10% (Fisher and Bogousslavsky, 2000) and usually leads
to selective delayed neuronal death (DND) of pyramidal
neurons in the hippocampus, especially in the cornu ammonis
area 1 (CA1) in experimental animal models (Pulsinelli and
Brierley, 1979; Kirino, 1982). The complicated mechanisms
of DND have been extensively studied. One of the critical
pathophysiological features of GCI is oxidative stress induced
by ischemia/reperfusion (I/R) injury (Liang et al., 2008). Thus,
reducing oxidative stress may be one of the logical approaches
for inhibiting DND and alleviating GCI.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is
considered an important cytoprotective regulator against
oxidative stress (Kensler et al., 2007). During oxidative stress,
Nrf2 is released from Kelch-like ECH-associated protein 1
(Keap1) in the cytoplasm, translocates into the nucleus and
up-regulates expression of many antioxidant and detoxification
genes, including HO-1, glutathione S-transferases (GSTs), and
NAD(P)H quinone oxidoreductase (Yang et al., 2015). Recent
evidence has proven that activation of Nrf2 can attenuate
oxidative injury induced by focal cerebral ischemia, which is
equivalent to translocation from the cytoplasm to the nucleus,
and promotes expression of a variety of antioxidant genes
(Chen et al., 2012; Li et al., 2013). Among these antioxidant
genes, HO-1 has been implicated to be particularly important in
neuroprotection against cerebral ischemia, as evidenced by HO-1
knockout mice exhibiting greater ischemic damage compared
to wild type mice (Kim et al., 2011). In addition, the HO-1
promoter is known to have a large number of ARE sequences to
which Nrf2 can bind to induce its expression in a preferential
manner (Kensler et al., 2007). Consequently, the Nrf2/HO-1
pathway might be considered a potential target against oxidative
stress in GCI.
Rifampicin is a member of a class of broad-spectrum
antibiotics that are fermentation products of Nocardia
mediterranea and is widely used against mycobacterium
tuberculosis (Blanchard, 1998; Yulug et al., 2004). It is formed
from napthohydroquinone or naphthoquinone chromophores
spanned by an aliphatic ansa chain (Tomiyama et al., 1996).
Recent findings have shown that rifampicin reduced apoptosis in
focal ischemic stroke and increased the survival of nigrostriatal
dopaminergic neurons in models of Parkinson’s disease (Yulug
et al., 2004; Oida et al., 2006; Chen et al., 2010). However, the
exact mechanisms of action remain unclear. It has not been
reported whether rifampicin inhibits DND after GCI. In the
present study, we hypothesized that rifampicin may decrease
DND by improving the ischemic tolerance of neurons by
Abbreviations: Nrf2, Nuclear factor erythroid 2-related factor; GCI, Global
cerebral ischemia; RFP, rifampicin; HO-1, Hemeoxygenase-1; COX-2,
Cyclooxygenase-2; DND, Delayed neuronal death.
promoting the activation of Nrf2 in the hippocampus CA1 after
GCI.
We have previously shown that COX-2 is a key enzyme
resulting in neuronal apoptosis in GCI (Cheng et al., 2010, 2011).
Nrf2 is also involved in reducing the expression of inflammation-
related factors, such as inducible nitric oxide synthase (iNOS),
COX-2 and IL-6, in LPS-stimulatedmacrophages and endotoxin-
shocked mice (Mo et al., 2014). Therefore, in the present study,
we investigated whether rifampicin could reduce expression of
COX-2 by activating Nrf2.
Our overall aim was to investigate whether rifampicin has
neuroprotective effects in the hippocampus of rats with GCI.
Furthermore, we also explored whether the protection provided
by rifampicin would occur through activation of the Nrf2/HO-1
pathway and reduce the expression of COX-2.
MATERIALS AND METHODS
Animals and Groups
Adult male Sprague Dawley rats weighing 250–300 g provided
by the Experimental Animal Center of Chong Qing Medical
University were used. All animal experiments were performed in
accordance with the guidelines for the care and use of laboratory
animals and the international guidelines for the ethical use of
laboratory animals. The study was approved by the Institutional
Animal Care and Use Committee at Chong Qing Medical
University. All efforts were made to minimize animal suffering,
reduce the number of animals used and utilize alternatives to in
vivo techniques, if possible. Rats were acclimatized for 7 days
before the experiments, had free access to food and tap water
and were maintained at 21 ± 2◦C under a 12 h dark and light
cycle.
Seventy two adult male SD rats were randomly assigned to
four groups that included a sham group and three treatment
groups with global ischemia [control (I/R group), rifampicin
(RFP group), and rifampicin plus brusatol (RFP + Bru, an
inhibitor of Nrf2)], 18 rats in each group. They were tested
behaviorally (n = 6), histopathology (n = 4), and molecular
biology (n = 4). I/R group underwent the GCI operation.
RFP group received the GCI operation and were also treated
with rifampicin. Rats in the RFP + Bru group received the
GCI operation and were also treated with rifampicin plus
brusatol.
Drug Treatment
Rifampicin (purchased from Huapont Pharm. Co., Chongqing,
China) was dissolved in saline used as a vehicle and diluted
to 2mg/ml. After 30min of reperfusion, rats received an
intraperitoneal injection of rifampicin (20mg/kg) or vehicle
for 7 days. All rats received left lateral ventricle puncture
(anteroposterior, −1.1mm; lateral, 1.5mm; depth, 4.5mm; from
bregma), in RFP + Bru group, 30 min prior to ischemia animals
received Nrf2 inhibitor brusatol by intracerebroventricular
infusion (1mg/kg, dissolved in 5 µl 1% DMSO). Sham-operated
group also received equal volume vehicle injection after surgery.
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Establishment of Transient Global
Ischemic Model
The animals were fasted for 12 h, but they were allowed free
access to water before surgery. Transient global ischemia was
induced in SD rats via the 2-vessel occlusion (2-VO) model.
The model and the criteria for model success and exclusion
were previously described (Cheng et al., 2012). Briefly, after
injection of 4% chloral hydrate (400mg/kg, i.p.), animals were
placed on a thermostat plate, and their body temperature was
maintained close to 37◦C. Both common carotid arteries were
exposed and carefully separated from the vagus nerve and
surrounding tissues, and the right jugular vein was cannulated.
Blood (2.5ml/100 g) was withdrawn via the jugular vein into a
warmed heparinized syringe, and then both carotid arteries were
temporary occluded with micro-aneurysm clips for 20 min. After
releasing the clamps, the extracted blood was slowly reinfused
and the incisions were sutured. Sham-operated animals, which
served as controls, were subjected to the same surgical procedures
but without occlusion of the carotid arteries and induction of
hypotension.
At 3 or 7 days after reperfusion, the animals were deeply
anesthetized and transcardially perfused with saline followed by
4% paraformaldehyde. The brains were removed and postfixed in
4% paraformaldehyde for at least 24 h at 37◦C. The slices at day
7 after reperfusion were embedded in paraffin, cut into coronal
serial sections (−3.3 to −4.5mm from Bregma) at a thickness
of 4 µm, and prepared for TUNEL and HE staining. The slices
at day 3 after reperfusion were dehydrated and cryoprotected in
gradient sucrose; frozen coronal sections (10 µm) were made
on a Leica sliding microtome and were cut from Bregma −3.3
to −4.5mm and used to perform immunofluorescence assays as
previously described (Cheng et al., 2010).
Morris Water Maze
Hippocampus-dependent spatial learning and memory abilities
were evaluated with the Morris water maze (MWM) test.
Briefly, the water maze (150-cm diameter) was divided into four
quadrants. A hidden platform (12-cm diameter) was placed 2 cm
below the water surface in the center of one quadrant during
pretraining and testing. The rats were subjected to pretraining
(the navigation test) on postoperative days 7–12 twice daily, in
the morning and afternoon, which was followed by testing (the
orientation test) without the platform.
During the pretraining, rats were released into the maze from
a randomly selected quadrant and with all animals using the same
order. The escape latency to find the underwater platform was
recorded. If the rat failed to reach the hidden platform within
60 s, then it was manually guided to the platform, where it was
placed for 15 s. Each animal performed four training sessions
from different starting quadrants per day. All animals had been
pre-trained for 4 consecutive days before the surgery. The escape
latency (seconds) and swimming speed (cm per second) were
analyzed. Data from trials in each daily session were averaged for
each rat.
To assess spatial learning ability, the platform was removed
from the pool, and the animals were subjected to a 60 s probe
trial following the last training session to fond the original
platform (target crossings). The proportion of time spent in
the target quadrant, the number of platform crossings, and
the swimming speed (cm per second) were monitored and
recorded by a video camera linked to a computer-based image
analyzer.
Hematoxylin and Eosin (HE) Staining
HE staining was performed to determine the neuronal loss in
both hippocampi of each animal. For HE staining, sections
were deparaffinized, hydrated, stained with hematoxylin for
3 min, differentiated by 1% hydrochloric acid alcohol for
1 s, and stained with eosin for 3 s. Stained sections were
dehydrated, mounted with neutral balsam, and covered with
a coverslip. The number of CA1 pyramidal cells was counted
at 400x magnification. Only cells with an obvious nucleus and
nucleolus were included. Images were taken by light microscope
(Olympus).
In-situ Detection of DNA Fragmentation
(TUNEL Staining)
For the analysis of neuronal apoptosis, TdT-mediated deoxy-
uridine triphosphate nick end labeling (TUNEL) staining was
used according to the manufacturer’s protocol of TUNEL
POD (Cat.No.11718096001, Roche, Germany). After being
deparaffinized with xylene and hydrated in decreasing
concentrations of alcohol solutions, the sections were treated
with 3% H2O2 diluted by methanol for 15 min, digested
by proteinase K solution for 60 min at 37◦C, treated with
Triton-X100 transparent (0.01%) for 20 min, added with
TUNEL reaction mixture (50ml) overnight at 4◦C, incubated
with POD for 60 min at 37◦C, and the POD of the sections
was demonstrated with DAB substrate kit (Lot: ZLI-9017,
Zhongshan). To reveal the nuclear morphology, sections
were further stained with hematoxylin. Finally, sections were
mounted with coverslips. Five slices were taken from each rat
brain. We randomly chose four non-overlapping view-fields
from hippocampal CA1 regions of both hemispheres from
each animal. The total number of apoptotic cells was counted
by an investigator who was blinded to the experimental
conditions and who performed all assessments at 400x
magnification.
Double Immunofluorescence Staining
After being washed in PBS, coronal sections were pretreated
with 0.3% Triton X-100 for 20 min at 37◦C and then
incubated with 3% bovine serum albumin for 30 min at
37◦C. Then, the sections were incubated overnight at 4◦C
with rabbit anti-Nrf2 (1:100, Abcam) and mouse anti-MAP2
(microtubule associated protein 2) antibody (1:50, Santa Cruz)
to label neurons. These antibodies were detected using the
appropriate fluorescence-labeled secondary antibodies at 1:100
(goat anti-mouse conjugated to DyLight 488 or goat anti-rabbit
conjugated to DyLight 549, Abbkine). DAPI (1 ng/µl) was used
for incubation for nucleus visualization. Finally, the sections
were coverslipped and analyzed by immunofluorescent confocal
microscopy (Leica, Germany).
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Western Blot Analysis
The animals were euthanized under general anesthesia on day 3
after surgery, and total protein, nuclear protein and cytoplasmic
protein were extracted from both hippocampus as described
previously (Cheng et al., 2010). Western blotting procedures
followed standard protocols (Shimamura et al., 2006). Equal
amounts (30 µg) of total protein and nuclear protein were
separated in 10% SDS-polyacrylamide gel and transferred to
PVDF membranes. Primary antibodies included anti-β-actin
(1:1000, Boster), anti-Histone H3 (1:1000, Millipore), anti-Nrf2
(1:1000, Abcam), anti-HO-1 (1:1000, Abcam), and anti-COX-2
antibody (1:1000, Abcam). Finally, protein bands were detected
using an enhanced chemiluminescence (ECL) kit (ThermoFisher
Scientific) according to the manufacturer’s protocol. The IOD
of each band was measured using a gel-image analyzing system
(Fusion Optix, USA). β-actin was used as an internal control to
normalize the target protein expression.
Statistical Analysis
Statistical analyses were performed using SPSS 19.0 (SPSS Inc.,
Chicago, IL, USA). All data are presented as the mean ± SD
(standard deviation). All data were performed by an investigator
who was blinded to the experimental conditions. Data recorded
in the navigation test (swimming velocity, escape latency,
Figure 1) were analyzed by two-way ANOVA with repeated
measures, followed by a LSD test for post-hoc comparisons
to compare differences between groups. The remaining data
were evaluated by one-way ANOVA, followed by the Student-
Newman–Keuls test for post hoc comparisons to compare
differences between groups (statistical significance, P < 0.05).
RESULTS
Morris Water Maze Test
The Navigation Test
The swimming velocity and mean latency for finding the
platform (escape latency) during the place navigation test are
shown in Figure 1. In all groups, the escape latencies showed
a progressive reduction over successive trials, especially in the
sham-operated and rifampicin-treated rats. The I/R group spent
a longer time searching for the hidden platform compared to
the sham group. The RFP group exhibited shorter exploration
times to find the hidden platform location compared to the I/R
group, and brusatol treatment prior to ischemia resulted in a
significantly longer escape latency for locating the submerged
platform during the first four trials, relative to rats that received
rifampicin treatment (Figure 1A, P < 0.05). It was observed that
all animals in all three groups could swim easily and with similar
swimming velocities at all time points (Figure 1B, P > 0.05).
The Orientation Test
The swimming velocity and number of crossings in the
orientation test are shown in Figure 1. The orientation test
was conducted by removing the platform and allowing the rat
to swim for 60 s to search for the platform. The number of
crossings over the platform location during the orientation test
was lower in the I/R group compared with Sham group, whereas
brusatol pretreated rats demonstrated a poorer performance
with Nrf2 inhibitor pretreatment versus rats receiving rifampicin
monotherapy (Figure 1C, P < 0.05). The swimming velocity did
not differ significantly (Figure 1D, P > 0.05) among the three
groups in this trial.
FIGURE 1 | Escape latency for the training trials (A) and velocity (B) during the place navigation stage. Number of crossings (C) and velocity (D) in the probe trial.
The data are expressed as the mean ± SD (n = 6 in each group). *p < 0.05 compared with I/R group, #p < 0.05 compared with RFP group.
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Hematoxylin and Eosin (HE) Staining
HE histology revealed characteristics of delayed cell death at
day 7. There was no significant neuronal damage or neuronal
loss in the hippocampal CA1 subregion in the sham group.
Pyramidal neurons were arranged in 2–3 cell layers, and in
individual neurons the nucleus was full, nucleolus was clear, and
cell outlines were clear (Figure 2). In the I/R group, the neurons
were sparsely arranged with fuzzy cell outlines, which revealed
marked neuronal damage, shrunken cell bodies, vacuolation and
pyknotic nuclei. The number of cells in the RFP group with an
eumorphism was larger than that in the I/R group. The pathology
was similar between rats pretreated with brusatol and those in the
I/R group.
TUNEL Staining
There were few TUNEL-positive cells in the sham group, whereas
a large number of TUNEL-positive neurons were observed in
the CA1 region of rats in the I/R group at day 7 after global
ischemia (Figure 3A). In contrast, the number of apoptotic cells
was significantly lower in the RFP group than in the I/R and
RFP+Bru groups (Figure 3B, p < 0.05).
Expression of Nrf2 in the Hippocampus
The band of Nrf2 protein expression (nucleus protein, cytoplasm
protein and total protein) was shown in Figure 4A. The
FIGURE 2 | Effects of rifampicin on ischemia-induced histological
changes in hippocampal CA1 neurons 7 days after ischemia (×200, HE
staining). Abnormal cells are indicated by the arrows.
cytoplasm protein levels of Nrf2 in the hippocampal CA1
neurons of I/R group rats were up-regulated compared with
those of the sham group (Figure 4D, p < 0.05). However, the
nucleus protein Nrf2 was not obviously increased compared
with the sham group (Figure 4C, p < 0.05). Rifampicin
treatment significantly increased the nucleus protein levels of
Nrf2 (Figure 4C, p < 0.05) and decreased the cytoplasm protein
levels of Nrf2 (Figure 4D, p < 0.05) compared with the I/R
group. Total protein levels of Nrf2 was shown in Figure 4E.
Compared to the sham group, there were no distinct differences
in the cytoplasm protein expression of Nrf2, but the nuclear
expression was significantly enhanced after rifampicin treatment.
Interestingly, brusatol pre-treatment markedly attenuated the
nuclear translocation of Nrf2 3 days after reperfusion. Further,
the representative images by confocal analysis of double
immunohistochemistry for Nrf2 and MAP2 revealed a higher
nuclear immunofluorescence in hippocampal CA1 neurons in
the RFP group compared to the I/R and RFP+Bru groups
(Figure 4B).
Expression of HO-1 in the Hippocampus
In the I/R group, we observed that protein level of HO-1 that was
no significant difference compared to the basal levels in the sham
group 3 days after reperfusion.Western blot analysis showed that,
consistent with the DNA binding activity of Nrf2, HO-1 levels
were significantly increased by rifampicin compared with the I/R
group 3 d after reperfusion. Brusatol attenuated this increase
(Figure 5).
Expression of COX-2 in the Hippocampus
In our previous study, GCI was shown to cause marked elevation
in COX-2 expression, which is responsible for neuronal injury or
death (Cheng et al., 2011). The levels of COX-2 were determined
in brain tissue using Western blot analysis. Western blotting
for COX-2 revealed that ischemic surgery led to a significant
increase in COX-2 levels in the I/R group relative to sham
group (Figure 6, p < 0.05). The treatment with rifampicin after
FIGURE 3 | (A) Effects of rifampicin (RFP) on the number of TUNEL-positive cells in the hippocampal CA1 region 7 days after ischemia (×200, TUNEL staining). (B)
Quantification was performed by counting the number of apoptotic-like neurons in the medial CA1 pyramidal cell layer (mean ± SD, n = 4 in each group).
Apoptotic-like neurons were shrunken cell bodies, stained brown (indicated by arrows). *p < 0.05 compared with I/R group, #p < 0.05 compared with RFP group.
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 November 2016 | Volume 10 | Article 273
Chen et al. Neuroprotection of Rifampicin through Nrf2
FIGURE 4 | Effects of rifampicin (RFP) on Nrf2 protein distribution. Representative blot of Nrf2 protein obtained from cytoplasmic, nuclear, and total extracts.
(A) Effects of rifampicin on Nrf2 protein distribution. (B) Immunofluorescence staining was performed for Nrf2 and MAP2 in hippocampal CA1 region 3 days after
reperfusion (magnification, 800×), scale = 40 µm. Data analyses for Nrf2 protein from the nuclear (C), cytoplasmic (D), and total extracts (E) expressed as the fold
change vs. the sham group (mean ± SD, n = 4 in each group).
†
p < 0.05 compared with sham group, *p < 0.05 compared with I/R group, #p < 0.05 compared with
RFP group.
surgery led to a notable reduction in COX-2 content compared
with the control group, whereas brusatol attenuated the decrease
(Figure 6, p < 0.05).
DISCUSSION
In the present study, we found several important findings.
First, rifampicin decreased the DND of pyramidal neurons
and improved cognitive impairments resulting from GCI.
Second, rifampicin also promoted nuclear translocation of Nrf2
in the CA1 region of the hippocampus and increased the
expression of HO-1. Third, the present study demonstrated that
rifampicin significantly inhibited the expression of COX-2 in the
hippocampus following GCI. Finally, all of these effects were
reversed by administration of brusatol, an inhibitor of Nrf2.
DND in the brain has been considered a central pathological
change in GCI. In rats subjected to GCI, it is accepted that
the cortex and hippocampus are the most vulnerable regions,
and GCI usually leads to selective DND of pyramidal neurons,
particularly in the CA1 region, which is associated with cognitive
dysfunction and disruption of spatial learning and memory in
rats (Cheng et al., 2012).
Although, evidence suggests that rifampicin ameliorates brain
damage in focal cerebral ischemia (Yulug et al., 2004), treatment
with rifampicin in GCI has not yet been investigated. Our results
showed that ischemic rats spent a longer time searching for
the hidden platform during the navigation test and showed
fewer crossings over the platform area in the orientation test.
However, the average swimming velocity was similar among
the groups in both the place navigation stage and probe trials,
which reveals that motor function was unaffected after GCI. After
administration of rifampicin, the performances in the MWM test
were significantly improved. This suggested that treatment with
rifampicin significantly ameliorated GCI/R-induced cognitive
dysfunction.
DNDwas mainly evidenced by apoptosis observed at 3–4 days
that peaked 7 days after GCI (Kirino et al., 1984; Kihara et al.,
1994; Nitatori et al., 1995). In this study, we found that pathologic
changes, including neuronal cell loss, smaller sizes, irregular
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FIGURE 5 | Effect of rifampicin on HO-1 levels in the hippocampus
(mean ± SD, n = 4). (A) Total protein in sham, vehicle, rifampicin, and
rifampicin+brusatol pre-treatment animals were subjected to Western blotting
for HO-1 and β-actin expression. (B) Blotting bands were scanned, and the
data are expressed as the fold change vs. the sham group. *p < 0.05
compared with I/R group, #p < 0.05 compared with RFP group.
FIGURE 6 | Effect of rifampicin on COX-2 levels in the hippocampus
(mean ± SD, n = 4). Representative Western blot and Western blot
quantitation normalized relative to β-actin. *p < 0.05 compared with I/R group,
#p < 0.05 compared with RFP group.
shapes, deepened cytoplasmic staining, and nuclei shrinkage after
ischemia, the pyramidal cells were ranged in order in sham
group as revealed by HE staining. After rifampicin treatment,
a significantly reduced number of TUNEL-positive cells and
increased number of surviving neurons was observed in the
hippocampus CA1 at 7 days compared with the I/R group. Our
experiments confirmed that rifampicin-related improvement
in cognitive functions after GCI was associated with reduced
cell apoptosis and increased survival of hippocampal CA1
neurons.
Oxidative injury was considered the main pathological
mechanism of DND (Chan et al., 1998). Nrf2 activation is
an important endogenous antioxidant mechanism that protects
against oxidative stress (Guo et al., 2015). During ischemia, the
expression level of Nrf2 is enhanced, and it is partly released
from Keap1 and translocated to the nucleus, where it triggers
the expression of several dozen cytoprotective proteins, such
as HO-1 and NAD(P)H (Saleem et al., 2008; Tulsulkar and
Shah, 2013). More importantly, that study found that promoting
the activation of Nrf2 has neuroprotective effects (Ding et al.,
2014). In this study, our data showed that, compared with
the sham group, the cytoplasm protein levels of Nrf2 in the
I/R group were up-regulated, whereas the Nrf2 protein was
not obviously increased in the nucleus. This demonstrated that
endogenous upregulation of Nrf2 was not sufficient to protect
neurons against GCI injury. Rifampicin significantly elevated
Nrf2 levels in the nucleus and simultaneously decreased them
in the cytoplasm. The double immunofluorescence for Nrf2
and MAP2 also showed a higher nuclear immunofluorescence
in hippocampal CA1 neurons of in the RFP group compared
to I/R group. HO-1, a target antioxidant enzyme of Nrf2, is
critical for the protection against ischemia and reperfusion (I/R)
injury in the brain, Parkinson’s disease, and other neurological
disorders (Calkins et al., 2009). Our data presented here
showed that rifampicin significantly improved the protein levels
of HO-1 on day 3 post-ischemia. However, when the Nrf2
inhibitor brusatol was added, the effects of rifampicin on HO-
1 protein expression were partially abolished. These findings
indicate that rifampicin-induced neuroprotective effects are
indeed responsible for the activation of the Nrf2/HO-1 pathway.
In addition, the rifampicin treatment plus Nrf2 inhibitor group
still showed a neuroprotective effect compared with the I/R
group. This finding suggests that in addition to the Nrf2/HO-
1 pathway, other mechanisms may be involved in rifampicin-
induced neuroprotection. Additionally, this dose of brusatol may
incompletely block Nrf2 in GCI. Previous studies confirmed that
rifampicin suppressed oxidative stress in rotenone-induced cell
death of PC12 cells, and this ability may be attributed to its
naphthohydroquinone ring (Chen et al., 2010). In models of
Parkinson’s disease, rifampicin could also ameliorate oxidative
stress, but the effect of rifampicin on the Nrf2/HO-1 pathway
was not discussed (Oida et al., 2006; Chen et al., 2010). In this
study, we confirmed that rifampicin increased ischemic tolerance
of CA1 neurons, which was associated with activation of the
Nrf2/HO1 pathway (Figure 7).
Accumulating evidence suggests that the enhanced COX-
2 involvement is involved in neuronal death during GCI
(Nakayama et al., 1998; Sasaki et al., 2004; Xiang et al., 2007).
Our previous studies also demonstrated that COX-2 promoted
neuronal apoptosis through caspase 3-dependent apoptosis
after GCI (Cheng et al., 2011). To confirm the relationship
between nuclear translocation of Nrf2 and neuronal apoptosis,
we measured the expression of COX-2 in the hippocampus.
We found that rifampicin-treated rats had higher nuclear Nrf2
expression that was accompanied by lower COX-2 expression
in the hippocampus compared with the I/R group. However,
brusatol, an inhibitor of Nrf2, could restore the expression of
COX-2. These results suggested that downregulation of COX-2
may be linked to activation of Nrf2. The finding that an agonist
of Nrf2 downregulated the expression of COX-2 was reported
in a previous study, where it occurred through inhibition of
nuclear factor kappaB (NF-kappaB) activation in vivo and in
vitro of colitis (Lee et al., 2007). Healy and colleagues reported
that activation of Nrf2 can directly interfere with the c-Jun
N-terminal kinase 2 signaling activity subsequent to negative
regulation of the expression of COX-2 in vitro in arthritis
(Healy et al., 2005). Therefore, consistent with these results,
our data demonstrated that COX-2 may be an important
downstream target of Nrf2 (Figure 7). However, further studies
are required to examine the downregulation of Nrf2 and to
determinate the link between Nrf2 and expression of COX-2
in vitro.
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FIGURE 7 | The possible neuroprotective mechanism of RFP in GCI. The neuron cells are faced with an insult such as oxidative stress after GCI, Nrf2 activation
is an important endogenous antioxidant mechanism that protects against oxidative stress. RFP significantly elevates Nrf2 levels in the nucleus, then Nrf2 binds to the
ARE and simultaneously promoting the expression of HO-1. In addition, the elevating of nuclear Nrf2 could inhibit the expression of COX-2, which may be mediated
by NF-κB. As the result, the cell apoptosis was reduced.
In conclusion, the present study demonstrates that rifampicin
can elicit its neuroprotective effect after GCI/R. The underlying
mechanisms may include activation of the Nrf2/HO-1 pathway,
which was in part blocked by brusatol. Meanwhile, expression
of COX-2 was also inhibited. We demonstrated the unexplored
potential of rifampicin for the treatment of GCI/R injury and
that pharmacological activation of the Nrf2 pathwaymay provide
neuroprotection.
The gender dependent significant differences in the cell death
pathways following ischemic insults and in pharmacotherapy and
some diseases have reported (Mathur et al., 2015; Rosano et al.,
2015). The limitations of this study is that only male rats were
used in present study, so biological sex difference of rifampicin
was not investigated.
AUTHOR CONTRIBUTIONS
BC: Manuscript Preparation, Research project Conceived, and
designed the experiments; HC:Manuscript Preparation, Research
project; BC, HC: Co-first author; LC, XY, XT, RL: Research
project; OC: Corresponding author, Manuscript Preparation,
Research project PI.
ACKNOWLEDGMENTS
This research was supported by the National Natural Science
Foundation of China (No.81471334, 81100981) and the
National Key Clinical Specialties Construction Program of
China.
REFERENCES
Blanchard, J. S. (1998). The ying and yang of rifampicin. Nat. Med. 4, 14–15.
doi: 10.1038/nm0198-014
Calkins, M. J., Johnson, D. A., Townsend, J. A., Vargas, M. R., Dowell, J.
A., Williamson, T. P., et al. (2009). The Nrf2/ARE pathway as a potential
therapeutic target in neurodegenerative disease. Antioxid. Redox Signal. 11,
497–508. doi: 10.1089/ars.2008.2242
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 November 2016 | Volume 10 | Article 273
Chen et al. Neuroprotection of Rifampicin through Nrf2
Chan, P. H., Kawase, M., Murakami, K., Chen, S. F., Li, Y., Calagui, B., et al. (1998).
Overexpression of SOD1 in transgenic rats protects vulnerable neurons against
ischemic damage after global cerebral ischemia and reperfusion. J. Neurosci. 18,
8292–8299.
Chen, L., Wang, L., Zhang, X., Cui, L., Xing, Y., Dong, L., et al. (2012). The
protection by octreotide against experimental ischemic stroke: up-regulated
transcription factor Nrf2, HO-1 and down-regulated NF-κB expression. Brain
Res. 1475, 80–87. doi: 10.1016/j.brainres.2012.07.052
Chen, S., Sun, Y., Zeng, Z., and Tao, E. (2010). Rifampicin inhibits
apoptosis in rotenone-induced differentiated PC12 cells by ameliorating
mitochondrial oxidative stress. Neural Regen. Res. 5, 251–256.
doi: 10.3969/j.issn.1673-5374.2010.04.002
Cheng, O., Li, Z., Han, Y., Jiang, Q., Yan, Y., and Cheng, K. (2012). Baicalin
improved the spatial learning ability of global ischemia/reperfusion
rats by reducing hippocampal apoptosis. Brain Res. 1470, 111–118.
doi: 10.1016/j.brainres.2012.06.026
Cheng, O., Ostrowski, R. P., Liu, W., and Zhang, J. H. (2010). Activation of liver X
receptor reduces global ischemic brain injury by reduction of nuclear factor-κB.
Neuroscience 166, 1101–1109. doi: 10.1016/j.neuroscience.2010.01.024
Cheng, O., Ostrowski, R. P., Wu, B., Liu, W., Chen, C., and Zhang, J. H.
(2011). Cyclooxygenase-2 mediates hyperbaric oxygen preconditioning in
the rat model of transient global cerebral ischemia. Stroke 42, 484–490.
doi: 10.1161/STROKEAHA.110.604421
Ding, Y., Chen, M., Wang, M., Wang, M., Zhang, T., Park, J., et al.
(2014). Neuroprotection by acetyl-11-keto-beta-Boswellic acid, in ischemic
brain injury involves the Nrf2/HO-1 defense pathway. Sci. Rep. 4:7002.
doi: 10.1038/srep07002
Fisher, M., and Bogousslavsky, J. (2000). Current Review of Cerebrovascular
Disease. Philadelphia, PA: Springer Science & Business Media.
Guo, Y., Yu, S., Zhang, C., and Kong, A. N. (2015). Epigenetic
regulation of Keap1-Nrf2 signaling. Free Radic. Biol. Med. 88, 337–349.
doi: 10.1016/j.freeradbiomed.2015.06.013
Healy, Z. R., Lee, N. H., Gao, X., Goldring, M. B., Talalay, P., Kensler, T. W.,
et al. (2005). Divergent responses of chondrocytes and endothelial cells to shear
stress: cross-talk among COX-2, the phase 2 response, and apoptosis. Proc. Natl.
Acad. Sci. U.S.A. 102, 14010–14015. doi: 10.1073/pnas.0506620102
Kensler, T. W., Wakabayashi, N., and Biswal, S. (2007). Cell
survival responses to environmental stresses via the Keap1-
Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89–116.
doi: 10.1146/annurev.pharmtox.46.120604.141046
Kihara, S., Shiraishi, T., Nakagawa, S., Toda, K., and Tabuchi, K. (1994).
Visualization of DNA double strand breaks in the gerbil hippocampal
CA1 following transient ischemia. Neurosci. Lett. 175, 133–136.
doi: 10.1016/0304-3940(94)91097-9
Kim, Y. M., Pae, H. O., Park, J. E., Lee, Y. C., Woo, J. M., Kim, N. H., et al.
(2011). Heme oxygenase in the regulation of vascular biology: from molecular
mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 14, 137–167.
doi: 10.1089/ars.2010.3153
Kirino, T. (1982). Delayed neuronal death in the gerbil hippocampus following
ischemia. Brain Res. 239, 57–69. doi: 10.1016/0006-8993(82)90833-2
Kirino, T., Tamura, A., and Sano, K. (1984). Delayed neuronal death in the rat
hippocampus following transient forebrain ischemia. Acta Neuropathol. 64,
139–147. doi: 10.1007/BF00695577
Lee, S. H., Sohn, D. H., Jin, X. Y., Kim, S. W., Choi, S. C., and
Seo, G. S. (2007). 2’,4’,6’-tris(methoxymethoxy) chalcone protects against
trinitrobenzene sulfonic acid-induced colitis and blocks tumor necrosis
factor-alpha-induced intestinal epithelial inflammation via heme oxygenase
1-dependent and independent pathways. Biochem. Pharmacol. 74, 870–880.
doi: 10.1016/j.bcp.2007.06.034
Li, L., Zhang, X., Cui, L., Wang, L., Liu, H., Ji, H., et al. (2013). Ursolic
acid promotes the neuroprotection by activating Nrf2 pathway after cerebral
ischemia in mice. Brain Res. 1497, 32–39. doi: 10.1016/j.brainres.2012.
12.032
Liang, H. W., Qiu, S. F., Shen, J., Sun, L. N., Wang, J. Y., Bruce, I. C., et al. (2008).
Genistein attenuates oxidative stress and neuronal damage following transient
global cerebral ischemia in rat hippocampus. Neurosci. Lett. 438, 116–120.
doi: 10.1016/j.neulet.2008.04.058
Mathur, P., Ostadal, B., Romeo, F., and Mehta, J. L. (2015). Gender-
related differences in Atherosclerosis. Cardiovasc. Drugs Ther. 29, 319–327.
doi: 10.1007/s10557-015-6596-3
Mo, C., Wang, L., Zhang, J., Numazawa, S., Tang, H., Tang, X., et al.
(2014). The crosstalk between Nrf2 and AMPK signal pathways is
important for the anti-inflammatory effect of berberine in LPS-stimulated
macrophages and endotoxin-shocked mice. Antioxid. Redox Signal. 20,
574–588. doi: 10.1089/ars.2012.5116
Nakayama, M., Uchimura, K., Zhu, R. L., Nagayama, T., Rose, M. E., Stetler, R.
A., et al. (1998). Cyclooxygenase-2 inhibition prevents delayed death of CA1
hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci. U.S.A.
95, 10954–10959. doi: 10.1073/pnas.95.18.10954
Nitatori, T., Sato, N., Waguri, S., Karasawa, Y., Araki, H., Shibanai, K., et al.
(1995). Delayed neuronal death in the CA1 pyramidal cell layer of the
gerbil hippocampus following transient ischemia is apoptosis. J. Neurosci. 15,
1001–1011.
Oida, Y., Kitaichi, K., Nakayama, H., Ito, Y., Fujimoto, Y., Shimazawa, M., et al.
(2006). Rifampicin attenuates theMPTP-induced neurotoxicity inmouse brain.
Brain Res. 1082, 196–204. doi: 10.1016/j.brainres.2006.01.116
Pulsinelli, W. A., and Brierley, J. B. (1979). A new model of bilateral
hemispheric ischemia in the unanesthetized rat. Stroke 10, 267–272.
doi: 10.1161/01.STR.10.3.267
Rosano, G. M., Lewis, B., Agewall, S., Wassmann, S., Vitale, C., Schmidt, H., et al.
(2015). Gender differences in the effect of cardiovascular drugs: a position
document of the working group on pharmacology and drug therapy of the ESC.
Eur. Heart J. 36, 2677–2680. doi: 10.1093/eurheartj/ehv161
Saleem, S., Zhuang, H., Biswal, S., Christen, Y., and Doré, S. (2008).
Ginkgo biloba extract neuroprotective action is dependent on heme
oxygenase 1 in ischemic reperfusion brain injury. Stroke 39, 3389–3396.
doi: 10.1161/STROKEAHA.108.523480
Sasaki, T., Kitagawa, K., Yamagata, K., Takemiya, T., Tanaka, S., Omura-Matsuoka,
E., et al. (2004). Amelioration of hippocampal neuronal damage after transient
forebrain ischemia in cyclooxygenase-2-deficient mice. J. Cereb. Blood Flow.
Metab. 24, 107–113. doi: 10.1097/01.WCB.0000100065.36077.4A
Shimamura, N., Matchett, G., Yatsushige, H., Calvert, J. W., Ohkuma, H., and
Zhang, J. (2006). Inhibition of integrin alphavbeta3 ameliorates focal cerebral
ischemic damage in the rat middle cerebral artery occlusion model. Stroke 37,
1902–1909. doi: 10.1161/01.STR.0000226991.27540.f2
Tomiyama, T., Shoji, A., Kataoka, K., Suwa, Y., Asano, S., Kaneko, H., et al.
(1996). Inhibition of amyloid beta protein aggregation and neurotoxicity by
rifampicin. its possible function as a hydroxyl radical scavenger. J. Biol. Chem.
271, 6839–6844. doi: 10.1074/jbc.271.12.6839
Tulsulkar, J., and Shah, Z. A. (2013). Ginkgo biloba prevents transient
global ischemia-induced delayed hippocampal neuronal death through
antioxidant and anti-inflammatory mechanism. Neurochem. Int. 62, 189–197.
doi: 10.1016/j.neuint.2012.11.017
Xiang, Z., Thomas, S., and Pasinetti, G. (2007). Increased neuronal injury in
transgenic mice with neuronal overexpression of human cyclooxygenase-2 is
reversed by hypothermia and rofecoxib treatment. Curr. Neurovasc. Res. 4,
274–279. doi: 10.2174/156720207782446342
Yang, Y., Jiang, S., Yan, J., Li, Y., Xin, Z., Lin, Y., et al. (2015). An overview of the
molecular mechanisms and novel roles of Nrf2 in neurodegenerative disorders.
Cytokine Growth Factor Rev. 26, 47–57. doi: 10.1016/j.cytogfr.2014.09.002
Yulug, B., Kilic, U., Kilic, E., and Bähr, M. (2004). Rifampicin
attenuates brain damage in focal ischemia. Brain Res. 996, 76–80.
doi: 10.1016/j.brainres.2003.10.012
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Chen, Cao, Chen, Yang, Tian, Li and Cheng. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 November 2016 | Volume 10 | Article 273
